Search PubMed⌕ Search

Biomedical subjects

F Tosato

Publications and source records attributed to F Tosato.

At least 55 records · Page 3Linked to original sources
PubMed1986

Total gastrectomy in the treatment of adenocarcinoma of the cardia. Review of the results in 73 resected patients.

Between January 1, 1971, and December 31, 1978, 73 patients with adenocarcinoma of the cardia were treated by total gastrectomy with distal esophagectomy. The continuity of the alimentary tract was restored by esophagojejunostomy using a Roux-Y procedure in 32 patients and jejunal loop interposition in 41 patients. The early postoperative mortality rate was 18 percent. The overall 5 year survival rate was 26.7 percent, and the 5 year survival rate for stage I and II disease was 91.6 percent and 25 percent, respectively, whereas none of the stage III and IV patients survived more than 4 years. Fifty-eight percent of the patients without nodal involvement lived more than 5 years. The 5 year survival rate was only 9.3 percent in the presence of nodal metastases. Our 5 year survival rates suggest the value of elective total gastrectomy for stage I or II adenocarcinoma of the cardia. Jejunal loop interposition is a time-consuming but functionally superior procedure in comparison to other reconstructive procedures after total gastrectomy.

Adenocarcinoma↗
PubMed1986

Monoclonal antibody defined T cell subsets in primary and secondary Sjögren's syndrome.

Using monoclonal antibodies of the OKT series we studied the blood T lymphocyte subsets of 12 patients with Primary Sjögren's Syndrome, 15 with Rheumatoid Arthritis associated Sjögren's Syndrome and 10 normal controls. We found a marked reduction of T lymphocytes both in Primary and Secondary Sjögren's Syndrome compared with normal controls (p less than 0.001). While no difference was noted in the number of helper-inducer T cells between Primary and Secondary Sjögren's Syndrome, a more important decrease of suppressor-cytotoxic cells was demonstrated in Secondary Sjögren's Syndrome (p less than 0.01). These data may contribute to a better understanding of the disease.

Antigens, Surface↗
PubMed1985

[Development of polycythemia vera during chronic idiopathic myelofibrosis].

A case of typical idiopathic myelofibrosis turning into polycythaemia vera 6 years after diagnosis is reported. This transformation occurred after treatment with busulphan. The present case is added to similar previous observations to give further support to the contention that the transition of chronic idiopathic myelofibrosis to polycythaemia vera may be a consequence, though rare, of therapy rather than a spontaneous event occurring during the course of the disease.

Adult↗
PubMed1985

Identification with monoclonal antibodies of T-cell subsets in peripheral blood and ascitic fluid of patients with alcoholic hepatic cirrhosis.

In an attempt to investigate an aspect of the immunoregulatory mechanisms operating in alcoholic hepatic cirrhosis with ascites we have enumerated T-cell subsets in the peripheral blood and ascitic fluid of 16 patients with this disease. The peripheral blood analysis revealed a reduction of OKT3+, OKT4+ and OKT8+ cells compared to those of the control group (p less than 0.001) and an increase of OKT4+/OKT8+ ratio. In the ascitic fluid the OKT4+/OKT8+ ratio, compared to that of the peripheral blood, was decreased (p less than 0.001) because of increase of OKT8+ cell proportion. We suggest that the sequestrated splanchnic OKT8+ subset might be represented by suppressor lymphocytes transuding from the liver.

Adult↗
PubMed1984

[Protocol of combined surgical and polychemico-immunoradiologic therapy of stage T2N2MO lung cancer].

Preliminary data on the use of a combined surgical-polychemical-immunoradiotherapy protocol in the treatment of 13 T2N2M0 lung cancer patients are reported. The results are compared with those obtained in a 13 patient control group, homogenous by histotype, stage and surgical treatment who were given no other therapy. At 24 months the average survival rate in the first group was 61.5% compared to 15.3% in the second. It was significant that survival at 24 months after pneumonectomy rose from 16.6% to 50% and even more significantly survival after lobectomy rose from 14.2% to 71.4%.

Antineoplastic Combined Chemotherapy Protocols↗